Redefining Post-Cardiac Arrest Care: Two-Year TTM2 Data Confirm No Long-Term Advantage for Targeted Hypothermia
Posted inCardiology Critical Care news

Redefining Post-Cardiac Arrest Care: Two-Year TTM2 Data Confirm No Long-Term Advantage for Targeted Hypothermia

This 2-year follow-up of the TTM2 trial demonstrates that targeted hypothermia at 33°C provides no long-term benefit for functional or cognitive recovery compared to targeted normothermia. The findings emphasize the importance of early fever management and suggest a recovery plateau after six months post-arrest.
GnRH Agonists Linked to Accelerated Coronary Plaque Progression Compared to Antagonists in Prostate Cancer Patients
Posted inCardiology news Oncology

GnRH Agonists Linked to Accelerated Coronary Plaque Progression Compared to Antagonists in Prostate Cancer Patients

A randomized clinical trial demonstrates that the GnRH agonist leuprolide leads to significantly greater coronary plaque progression, specifically noncalcified plaque, compared to the antagonist relugolix in men with prostate cancer, offering a potential biological explanation for differential cardiovascular risks.
Standardized DOAC Interruption Protocols Result in Low Residual Levels, but Apixaban and Renal Impairment Merit Closer Monitoring
Posted inCardiology General Surgery news

Standardized DOAC Interruption Protocols Result in Low Residual Levels, but Apixaban and Renal Impairment Merit Closer Monitoring

The DALI cohort study reveals that while current DOAC interruption protocols are generally effective, 13.1% of apixaban users maintain levels ≥30 ng/mL before surgery. However, these residual levels did not correlate with increased surgical blood loss, suggesting other factors drive perioperative bleeding.
Redefining Anticoagulation Safety in the Elderly: Abelacimab Drastically Reduces Bleeding Risk in Phase 2b AZALEA-TIMI 71 Analysis
Posted inCardiology Hematology-Oncology news

Redefining Anticoagulation Safety in the Elderly: Abelacimab Drastically Reduces Bleeding Risk in Phase 2b AZALEA-TIMI 71 Analysis

A prespecified analysis of the AZALEA-TIMI 71 trial demonstrates that the Factor XI inhibitor abelacimab significantly reduces bleeding risk compared to rivaroxaban in older patients with atrial fibrillation, potentially offering a safer alternative for high-risk geriatric populations.
Anatomically Directed HGF Gene Therapy Significantly Accelerates Ulcer Healing in Chronic Limb-Threatening Ischemia: Insights from the LEGenD-1 Trial
Posted inCardiology General Surgery news

Anatomically Directed HGF Gene Therapy Significantly Accelerates Ulcer Healing in Chronic Limb-Threatening Ischemia: Insights from the LEGenD-1 Trial

The LEGenD-1 trial demonstrates that intramuscular HGF gene therapy (AMG0001) significantly reduces healing time for neuroischemic ulcers in patients with moderate chronic limb-threatening ischemia, offering a potential nonsurgical therapeutic breakthrough for an underserved patient population.